Document is current
Any future updates will be listed below
-
Authors
Dailamy, Amir
Lyu, Weiqi
Nourreddine, Sami
Tong, Michael
Rainaldi, Joseph
McDonald, Daniella
Panwala, Rebecca
Muotri, Alysson
Breen, Michael S.
Zhang, Kun
Mali, Prashant https://orcid.org/0000-0002-3383-1287
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG012351)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OT2OD032742)
U.S. Department of Defense (W81XWH-22-1-0401)
- License Information
-
More Information
Article History
Received: 4 December 2023
Accepted: 28 October 2024
First Online: 13 November 2024
Competing interests
: P.M. is a scientific co-founder of Shape Therapeutics, Boundless Biosciences, Navega Therapeutics, Pi Bio, and Engine Biosciences. A.M. is the co-founder of and has an equity interest in TISMOO, a company dedicated to genetic analysis and human brain organogenesis, focusing on therapeutic applications customized to autism spectrum disorders and other neurological diseases. K.Z. is a full-time employee and equity holder of the Altos Labs. The remaining authors declare no competing interests. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.
